Clene
Clene

Clene

Pharmaceuticals
WebsiteInvestor RelationsSEC
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.

$50.4M

Market Cap • 10/7/2026

2013

(13 years)

Founded

2020

(6 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

—

P/S

255,7

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

—

EPS

—

Market Cap

Market Cap

50,4M

EV

63M

EV/Revenue

320

EV/EBITDA

-3,3

EV/EBIT

-3,1

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-34,1%

Total Yield

-34,1%

Payout

0%

Retained Earnings

-329,8M

Profitability

Gross Margin

70,1%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

6505,6%

Capex/Revenue

20,3%

Capex/D&A

2,8%

Capex/OCF

-0,3%

SBC/OCF

—

% PPE

35%

% Goodwill

0%

ROE

237,2%

ROIC

—

Growth

CAGR Revenue 5Y

-18,3%

CAGR Op. Income 5Y

-11,2%

CAGR Net Income 5Y

-5,6%

CAGR EPS 5Y

-60,4%

CAGR OCF 5Y

-12,6%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

3,1

Quick Ratio

2

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium